Bill > HB1881

This bill adds xylazine to the list of Schedule III controlled substances, with specific provisions for its use in veterinary medicine. The bill allows for certain exceptions to the scheduling, such as using xylazine in animal drugs approved by the U.S. Secretary of Health and Human Services, using xylazine for permissible animal treatments, manufacturing or distributing xylazine as an active pharmaceutical ingredient for approved animal drugs, and pharmaceutical compounding by licensed professionals. Xylazine, which is a sedative and pain medication primarily used in veterinary practice, will now be regulated under controlled substance guidelines, meaning its production, distribution, and use will be more strictly monitored. The bill includes a specific implementation date of January 1, 2026, for the various exceptions and provisions related to xylazine's use, giving stakeholders time to adjust to the new regulatory framework. This scheduling aims to address growing concerns about the potential misuse of xylazine, particularly in the context of drug abuse and public health.

Health and Social Services

https://house.mo.gov/Bill.aspx?bill=HB1881&year=2026&code=R